United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer's stock has underperformed the market due to declining revenue and profits on a YoY basis, but it is essential to understand that last year was an anomaly. The company's recent earnings showed a decline in revenue but compared to pre-vaccination levels, revenue has increased by 8% and profitability metrics remain strong. The stock is undervalued and has a target price of $40 according to a dividend discount model, making it an attractive investment opportunity.

Pfizer: Ignore The Noise And Buy This Deep Value

Roche Holding AG

Roivant Sciences Ltd

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. Roivant made $5 billion from the sale, after having only spent $15 million on development. Pfizer originally passed it over to Roivant for free last December.

A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

According to screenshots posted to Reddit, Pfizer employees complained about their boss laughing and “chilling” during the call. While other industries got reamed by the pandemic, it's said that pharmaceutical giant Pfizer “won” by moving tens of billions of dollars worth of COVID-19 medicine—enough to still report “all-time-high revenues” just months ago.

Pfizer's ‘casual' layoffs livestream is the next Better.com CEO gaffe—and workers are livid

Pfizer shares are now trading at pre-Covid levels, presenting a significant buying opportunity. The company has built up a strong cash reserve since Covid, allowing for accelerated R&D, the Seagen acquisition, and a robust product pipeline. Our DCF Model indicates a 100% upside for the stock. We wouldn't be surprised if Pfizer goes above that.

Pfizer: Huge Upside Potential And 5%+ Yield

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect

Pfizer Inc (NYSE:PFE) is scheduled to report earnings on October 31 before the opening bell, but if past results are any indication, the pharmaceutical giant's earnings won't be spooky.  The Street consensus for Pfizer is a loss of $0.32 per share on revenue of $12.72 billion, compared to earnings of $1.51 per share on revenue of $22.64 billion a year earlier.

Pfizer hopes to avoid scaring investors when it reports 3Q results on Halloween

London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is co-owned by Pfizer (PFE), to Roche Holding for $7.1 billion.

Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion

Pfizer Inc.'s acquisition of Seagen is the latest in a series of M&A deals fueled by pandemic-related profits. Despite the underperformance of Pfizer shares, the current share price shows potential appeal if operational discipline returns. Pfizer's organic business is now valued at roughly half of its pre-pandemic valuation, but cost savings efforts and organic growth could stabilize performance.

Pfizer Stock: Interesting, If Discipline Returns

Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billion.

Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion

Citigroup

Energy Transfer LP Unit

Altria

Simon Property Group

Truist Financial

Verizon

For growth and income investors, it makes sense now to look at blue chip dividend stocks with big and dependable payouts.

Altria Stock and 6 More ‘Strong Buy' Blue Chips Yielding Up to 9%

The deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs.

Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion

Moderna

While Pfizer Inc. (NYSE: PFE) was literally printing money during the Covid pandemic, those days are gone.

Pfizer and Moderna Stock Wrecked as Covid Vaccine Sales Dry Up

Pfizer is going to be trimming its headcount over the next 12 months. Its best-selling drugs of the last few years are no longer raking in lots of dough.

Pfizer Just Announced Layoffs. Should You Still Buy the Stock?

Pfizer's revenue has taken a big hit because of lower COVID-19-related sales. Roche just released third-quarter earnings.

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?

Pfizer recently cut its annual earnings guidance as demand for coronavirus products shrinks. Still, the company is in the middle of one of its most aggressive series of product launches ever -- aiming for 19 launches over 18 months.

Is Pfizer a Bad News Buy Right Now?

LOS ANGELES--(BUSINESS WIRE)-- #BigPharma--The AIDS Healthcare Foundation (AHF) rebuked pharmaceutical giant Pfizer today for announcing that it plans to charge $1,400 for a five-day course of the COVID-19 antiviral drug Paxlovid. During the pandemic, the U.S. government only paid $529 for the same drug. “This is yet another example of rampant drug profiteering off the backs of sick people by Big Pharma. The same drug, with the same efficacy, will suddenly cost nearly three times as much when it reaches the.

Patients Suffer as Pfizer Pockets Profits, says AHF

Pfizer Inc. PFE, -1.80% said Friday that the U.S. Food and Drug Administration has approved the first five-in-one vaccine designed to protect teenagers and young adults against meningococcal disease.

Pfizer gets FDA green light for new shot that can streamline teenagers' vaccinations

The U.S. Food and Drug Administration (FDA) has approved Pfizer's vaccine Penbraya, making it the first shot to protect against five groups of a deadly bacteria that can cause meningitis and blood poisoning, the company said on Friday.

US FDA approves Pfizer's vaccine for meningococcal disease

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. PENBRAYA combines the components from two meningococcal vaccines, Trumenba® (meningococcal group B vaccine) and Nimenrix® (m.

FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

The new cost of the drug is nearly triple the amount the US government paid during the coronavirus pandemic, according to a report.

Pfizer jacks up price of five-day course of COVID drug Paxlovid to $1,400

BioNTech SE

Novavax

Novavax NVAX, -5.56% stands out as a stark reminder of the biotech sector's faltering steps in 2023. Once renowned for its Nuvaxovid COVID-19 vaccine, the Maryland-based company is now grappling with financial issues, reflecting the broader challenges that continue to plague the pharmaceutical sector this year.

Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionable

AbbVie

Devon Energy

Kellogg

Microsoft

NextEra Energy

Realty Income Corp

Recently, investors searching for dividend stocks to buy have seen more opportunity. Some looking for income over a longer term horizon have flooded into the bond market.

7 Dividend Stocks to Buy and Hold Forever and Ever

Bristol-Myers

Johnson & Johnson

Eli Lilly

McKesson

Procter & Gamble

Walgreens

This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

Pfizer Inc. will charge $1,390 for a five-day course of its Paxlovid COVID-19 antiviral when the drug moves to the commercial market later this year. That's more than double the amount the company charged the U.S. government during the pandemic.

News for Pfizer Stock (PFE)